TY  - GEN
AU  - Bele,Mrudula H.
TI  - Section 3(d) for precluding patent evergreening: India's attempts to improve access to medicines
KW  - фармацевтические препараты
KW  - патенты
KW  - Индия
KW  - статьи в сборниках
N1  - Библиогр. в подстроч. примеч
N2  - In the year 2013, India created a stir in the world of pharmaceutical
patents by rejecting patent application of Novartis’ anticancer drug,
 Glivec1. This rejection was based on section 3(d) of the Indian patent act2
 which precludes evergreening of pharmaceutical patents yet claims to promote
 incremental inventions. This report discusses the necessity of a bright
 line statute like section 3(d) in a country like India, which has become
 pharmacy of the developed world, and yet needs to promote access to cheap
 medicines due to low human development index. This necessity has been
 examined by studying India’s unique position between the developing and
 developed status, infrastructure and human resource at the patent office,
 training of patent examiners and the awareness about patent litigations in India.
 The report also compares provisions of precluding patent evergreening
 by some other countries, with a statute like section 3(d). After giving due
UR  - http://vital.lib.tsu.ru/vital/access/manager/Repository/vtls:000669793
ER  -